Fundz
Funding, M&A and exec moves matched to your market — guaranteed to pay for itself in a year, or we refund it.See plans →

Sudarshan Pharma to acquire USFDA unit in Visakhapatnam

PRIVATEAug 14, 20262 days ago

Acquiring Company

Sudarshan Pharma Industries Ltd

Acquired Company

USFDA-approved manufacturing facility

VisakhapatnamVisakhapatnamManufacturingBiotechnologyPharmaceuticalManufacturingBiotechnology

Description

Sudarshan Pharma Industries Ltd has proposed the acquisition of a USFDA-approved manufacturing facility located in Visakhapatnam. The facility, which specializes in Active Pharmaceutical Ingredients, has significant operational capabilities and important regulatory certifications. This acquisition aims to enhance Sudarshan Pharma's production capacity and offer a broader range of pharmaceutical solutions. The company submitted details of the acquisition to the BSE on August 14, 2026.

Company Information

Company

Sudarshan Pharma Industries Ltd

Location

Visakhapatnam, Andhra Pradesh, India

About

Sudarshan Pharma Industries Ltd is a pharmaceutical company specializing in the production of Active Pharmaceutical Ingredients (APIs). The company focuses on meeting international quality standards with a strong commitment to regulatory compliance. It employs advanced manufacturing processes and technologies to deliver high-quality pharmaceutical products. Sudarshan Pharma has a well-established reputation in the pharmaceutical industry.

Don't miss Sudarshan Pharma Industries Ltd's next move

Get an email the moment Sudarshan Pharma Industries Ltd makes an acquisition, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Sudarshan Pharma Industries Ltd's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired USFDA-approved manufacturing facility?

USFDA-approved manufacturing facility was acquired by Sudarshan Pharma Industries Ltd, based in Visakhapatnam. The deal was reported on August 14, 2026. Sudarshan Pharma Industries Ltd is a pharmaceutical company specializing in the production of Active Pharmaceutical Ingredients (APIs). Sudarshan Pharma Industries Ltd is privately held and operates in Manufacturing.

When did Sudarshan Pharma Industries Ltd acquire USFDA-approved manufacturing facility?

Sudarshan Pharma Industries Ltd's acquisition of USFDA-approved manufacturing facility was reported on August 14, 2026. Sudarshan Pharma Industries Ltd has proposed the acquisition of a USFDA-approved manufacturing facility located in Visakhapatnam. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does USFDA-approved manufacturing facility do?

The USFDA-approved manufacturing facility specializes in producing Active Pharmaceutical Ingredients (APIs) and API intermediates. It is privately held, operating in Manufacturing, and is based in Visakhapatnam.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.